Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Amyloidosis Clinical Trials

102 recruiting trials for Amyloidosis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
102
Total Trials
102
Recruiting Now
7
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGNCT07130565

Pan-Amyloid PET/CT in Various Amyloid-Related Disease

To evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions...

Sponsor: Tianjin Medical UniversityEnrolling: 5002 locations
RECRUITINGNCT06251778

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue...

Sponsor: Paolo MilaniEnrolling: 2001 location
RECRUITINGNCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in...

Sponsor: xCuresEnrolling: 10001 location
RECRUITINGNCT04265040

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research...

The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical...

Sponsor: University Hospital HeidelbergEnrolling: 20401 location
RECRUITINGNCT07301892

Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis

Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the...

Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical SciencesEnrolling: 1001 location
RECRUITINGNCT06573723

Institutional Registry of Rare Diseases

The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD)....

Sponsor: Hospital Italiano de Buenos AiresEnrolling: 3801 location
RECRUITINGPhase 2NCT07285044

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve...

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer...

Sponsor: Mayo ClinicEnrolling: 271 location
RECRUITINGPhase 1 / Phase 2NCT07081646

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL...

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 9118 locations
RECRUITINGPhase 2NCT06935162

Teclistamab in Previously Treated AL Amyloidosis

This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab

Sponsor: Peking Union Medical College HospitalEnrolling: 301 location
RECRUITINGNCT05101304

Registre HEAR, Healthcare European Amyloidosis Registry

This is a non-interventional, prospective, retrospective, non-comparative, multi-center study. In order not to interfere with patient management, the study is observational....

Sponsor: Saving Lives MattersEnrolling: 50001 location
RECRUITINGPhase 2NCT05709314

A Study of AMDX-2011P in Participants With CAA

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral...

Sponsor: Amydis Inc.Enrolling: 251 location
RECRUITINGNCT01137825

Registry of Older Patients With Cancer

RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 30007 locations
RECRUITINGPhase 1 / Phase 2NCT06634108

Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy

This Phase 1b/2a study aims to investigate the safety and efficacy of genistein in patients with Transthyretin (TTR) Amyloidosis. The focus is on its impact on inflammatory and...

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sEnrolling: 201 location
RECRUITINGNCT02952144

Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis

Dialysis-related amyloidosis (DRA) is a serious complication of long-term hemodialysis (HD). Its pathogenic mechanism involves accumulation of β2-microglobulin (β2M) in the blood....

Sponsor: Kaneka Medical America LLCEnrolling: 401 location
RECRUITINGNCT02641145

Molecular Imaging of Primary Amyloid Cardiomyopathy

Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a...

Sponsor: Brigham and Women's HospitalEnrolling: 1711 location
RECRUITINGPhase 2NCT05331144

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease...

Sponsor: Rong ZhangEnrolling: 1801 location
RECRUITINGNCT01137643

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future....

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 150001 location
RECRUITINGNCT06845644

Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients

The pathophysiological process common to neuropathies is fatty replacement of muscle tissue, more commonly known as intramuscular fat fraction (F.F). MRI is an imaging technique...

Sponsor: Assistance Publique Hopitaux De MarseilleEnrolling: 1201 location
RECRUITINGNCT06733714

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation...

BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological...

Sponsor: Universidade Federal do Rio de JaneiroEnrolling: 401 location
RECRUITINGPhase 2NCT06649695

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab

Sponsor: European Myeloma Network B.V.Enrolling: 3010 locations
RECRUITINGNCT06527521

Prevalence of Amyloidosis in Trauma Patients

This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.

Sponsor: Consorci Sanitari de l'Alt Penedès i GarrafEnrolling: 2461 location
RECRUITINGPhase 1 / Phase 2NCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

Sponsor: Nexcella Inc.Enrolling: 4018 locations
RECRUITINGNCT07435168

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no...

Sponsor: Rigshospitalet, DenmarkEnrolling: 3001 location
RECRUITINGNCT05999084

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive...

Sponsor: Emory UniversityEnrolling: 7358 locations
RECRUITINGNCT05629000

Optimization Strategy of Carotid Artery Stenosis

The goal of this observational study is to learn about how to utilize multiple evaluation techniques in carotid artery stenosis patients for optimizing assessment of diagnosis and...

Sponsor: Peking Union Medical College HospitalEnrolling: 10001 location
RECRUITINGNCT05697861

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Sponsor: Intellia TherapeuticsEnrolling: 724 locations
RECRUITINGNCT06866912

Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis

observational epidemiological study of patients affected by systemic amyloidosis

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 7501 location
RECRUITINGPhase 4NCT05489523

Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic...

Transthyretin cardiac amyloidosis (ATTR-CA) is a relentlessly progressive disease that can progress to end stage heart failure, at which point recently approved transthyretin...

Sponsor: University of Texas Southwestern Medical CenterEnrolling: 254 locations
RECRUITINGNCT06205953

A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis...

A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study...

Sponsor: Fondazione IRCCS Policlinico San Matteo di PaviaEnrolling: 4006 locations
RECRUITINGNCT00935090

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's...

Sponsor: Barbara Ann Karmanos Cancer Institute1 location
RECRUITINGNCT05059158

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic...

Sponsor: Ludwig-Maximilians - University of MunichEnrolling: 601 location
RECRUITINGNCT06360289

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin...

This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and...

Sponsor: Alnylam PharmaceuticalsEnrolling: 5001 location
RECRUITINGNCT07402356

VR Pupillometry in Cognitive Impairment

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective,...

Sponsor: Max-Planck-Institute of PsychiatryEnrolling: 1401 location
RECRUITINGNCT05379101

Intracardiac Flow Assessment in Cardiac Amyloidosis

The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis.

Sponsor: Mayo ClinicEnrolling: 1001 location
RECRUITINGNCT03472664

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults...

Sponsor: Wake Forest University Health SciencesEnrolling: 1201 location
RECRUITINGPhase 2NCT07039578

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis

Sponsor: Keymed Biosciences Co.LtdEnrolling: 902 locations
RECRUITINGNCT06803082

The Impact of Systemic Light Chain Amyloidosis on Eyes

Study Purpose and Principle: Amyloidosis is a group of diseases characterized by the deposition of amyloid proteins in tissues and organs throughout the body, with common affected...

Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen UniversityEnrolling: 1301 location
RECRUITINGNCT06939374

Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A...

ICECAP is a multi-centre, prospective, single-arm, interventional, traditional feasibility clinical investigation to evaluate the efficacy and safety of intra-coronary cryotherapy...

Sponsor: Cryotherapeutics SAEnrolling: 303 locations
RECRUITINGNCT00869817

Dominantly Inherited Alzheimer Network (DIAN)

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Sponsor: Washington University School of MedicineEnrolling: 70020 locations
RECRUITINGPhase 2NCT05898646

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment...

Sponsor: Mayo ClinicEnrolling: 962 locations
RECRUITINGNCT07482072

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully...

Sponsor: Rigshospitalet, DenmarkEnrolling: 601 location
RECRUITINGPhase 3NCT07207811

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in...

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin...

Sponsor: Novo Nordisk A/SEnrolling: 128020 locations
RECRUITINGNCT07358078

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with...

Sponsor: Alnylam PharmaceuticalsEnrolling: 20004 locations
RECRUITINGNCT07033715

Exercise in Hereditary ATTR (ATTRv) Amyloidosis

This study aims to explore the effects of a 12-week exercise intervention on the physical and mental health of people living with Hereditary ATTR (ATTRv) Amyloidosis, a rare...

Sponsor: University of MaiaEnrolling: 421 location
RECRUITINGNCT06376214

Daratumumab for Patients With Light Chain Amyloidosis

This is a prospective, single-center study exploratory clinical trial, aim to exploring the efficacy and safety of daratumumab in patients with AL amyloidosis, patients were...

Sponsor: Nanjing University School of MedicineEnrolling: 1001 location
RECRUITINGNCT07124377

Phenotypic Manifestations of Hereditary ATTR Amyloidosis

This study focuses on hereditary transthyretin amyloidosis (ATTRv) with the Val50Met variant in a non endemic aerea

Sponsor: Hospital 9 de Julio de Las BreñasEnrolling: 572 locations
RECRUITINGNCT06197165

Amylo-Shiatsu-Acute-Chronic: Effects of Shiatsu on Symptoms and Quality of Life of Amyloidosis Patients

The objective of this study is to assess the beneficial effects of three targeted Shiatsu sessions compared to "comfort" Shiatsu on symptoms in patients with severe cardiac...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1081 location
RECRUITINGPhase 3NCT06128629

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Sponsor: Intellia TherapeuticsEnrolling: 120020 locations
RECRUITINGNCT06322667

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g.,...

Sponsor: Eisai Co., Ltd.Enrolling: 50003 locations

Showing 50 of 102 trials.Search all Amyloidosis trials

Frequently Asked Questions

There are currently 102 clinical trials for Amyloidosis, with 102 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Amyloidosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 7 Phase 3 trials for Amyloidosis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.